In silico Pharmacological Evaluation of Tetrahydro-β-carboline Derivatives as Putative Inhibitors of Alpha-Synuclein and Dopa Decarboxylase for Parkinson’s Disease
DOI:
https://doi.org/10.48048/tis.2023.6008Keywords:
Parkinson’s disease, Alpha-synuclein, Dopa decarboxylase, Lewy bodies, Molecular docking, In silico ADMET, β-carboline alkaloids, Central nervous systemAbstract
Parkinson’s disease (PD) is a neurological problem that results mostly in disability globally due to therapeutic challenges. Alpha-synuclein (ASN) and Dopa decarboxylase (DDC) are strongly implicated in the pathogenesis of PD including the aggregation of Lewy bodies and degeneration of dopamine-producing cells. These make them plausible drug targets commonly explored by researchers in the quest for potent inhibitors. However, up to this moment, no inhibitor of ASN has been approved for clinical application while only a handful is available for DDC, as such, searching for effective inhibitors of the dual targets remains essential. In this study, the in-house databases of tetrahydro-β-carboline and carbazole derivatives were virtually screened for putative ligands with multitarget inhibitory mechanisms against the ASN and DDC using molecular docking protocols. Relevant drugs such as phenylbutyrate, anle138b, levodopa, carbidopa and benserazide were used as references. The physicochemical, pharmacokinetics, pharmacodynamics and toxicological profiles of the selected ligands and references were also evaluated in silico using pkCSM. From the virtual screening, ligands 172, 082 and 013 interacted more strongly with ASN receptors with SP glide gscores of –9.154, –9.124 and –8.971 kcal/mol respectively as compared to phenylbutyrate and anle138b with SP glide gscores of –7.181 and –5.875 kcal/mol. They also showed higher binding affinities to DDC receptor by higher SP glide gscores of –6.758, –5.212 and –6.271 kcal/mol than levodopa, carbidopa and benserazide with values of –4.217, –4.502 and –4.18 kcal/mol respectively. Among the 3 ligands, ligand 172 satisfies Lipinski’s Rules of 5 (RO5) and demonstrates ADMET parameters that favor a central nervous system (CNS) drug which was identified as potent inhibitors of ASN and DDC responsible for PD. The potential ligands with stronger inhibitory interactions and good ADMET profile are amenable for further experimental validation in the quest for potent inhibitors of ASN and DDC as anti-PD agents.
HIGHLIGHTS
- Parkinson’s disease (PD) is a complex neurological disorder
- No effective medication has been approved for PD treatment
- Alpha-synuclein and dopa decarboxylase are relevant therapeutic targets
- Putative inhibitors are identified from tetrahydro-β-carboline (THBC) derivatives
- THBC derivatives deserve further studies as promising candidates for PD
GRAPHICAL ABSTRACT
Downloads
Metrics
References
F Daidone, R Montioli, A Paiardini, B Cellini, A Macchiarulo, G Giardina, F Bossa and CB Voltattorni. Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors. PLos One 2012; 7, e31610.
JT Boyd, C English and KM Lounsbury. 13 - Antiparkinson drugs. Pharmacol. Therapeut. Dent. 2017; 2017, 193-205.
Z Ou, J Pan, S Tang, D Duan, D Yu, H Nong and Z Wang. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front. Publ. Health 2021; 9, 776847.
HG Jasutkar, SE Oh and MM Mouradian. Therapeutics in the pipeline targeting α-synuclein for Parkinson’s disease. Pharmacol. Rev. 2022; 74, 207-37.
CR Fields, N Bengoa-Vergniory and R Wade-Martins. Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front. Mol. Neurosci. 2019; 12, 299.
P Burkhard, P Dominici, C Borri-Voltattorni, JN Jansonius and VN Malashkevich. Structural insight into Parkinson’s disease treatment from drug-inhibited DOPA decarboxylase. Nat. Struct. Biol. 2001; 8, 963-7.
JA Davies. Benserazide. In: xPharm: The comprehensive pharmacology reference. Elsevier, Netherlands, 2007.
YO Ayipo, MN Mordi, M Mustapha and T Damodaran. Neuropharmacological potentials of β-carboline alkaloids for neuropsychiatric disorders. Eur. J. Pharmacol. 2021; 893, 173837.
YO Ayipo, I Ahmad, YS Najib, SK Sheu, H Patel and MN Mordi. Molecular modelling and structure-activity relationship of a natural derivative of o-hydroxybenzoate as a potent inhibitor of dual NSP3 and NSP12 of SARS-CoV-2: In silico study. J. Biomol. Struct. Dynam. 2023; 41, 1959-77.
YO Ayipo, WA Alananzeh, SN Yahayaa and MN Mordi. Molecular modelling and virtual screening to identify new piperazine derivatives as potent human 5-HT1A antagonists and reuptake inhibitors. Combin. Chem. High Throughput Screen. 2022, https://doi.org/10.2174/1386207325666220524094913
SK Burley, C Bhikadiya, C Bi, S Bittrich, L Chen, GV Crichlow, CH Christie, K Dalenberg, LD Costanzo, JM Duarte, S Dutta, Z Feng, S Ganesan, DS Goodsell, S Ghosh, RK Green, V Guranović, D Guzenko, BP Hudson, CL Lawson, ..., M Zhuravleva. RCSB protein data bank: Powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res. 2021; 49, D437-51.
YO Ayipo, WA Alananzeh, I Ahmad, H Patel and MN Mordi. Structural modelling and in silico pharmacology of β-carboline alkaloids as potent 5-HT1A receptor antagonists and reuptake inhibitors. J. Biomol. Struct. Dynam. 2022, https://doi.org/10.1080/07391102.2022.2104376.
A Castro-Alvarez, AM Costa and J Vilarrasa. The performance of several docking programs at reproducing protein-macrolide-like crystal structures. Molecules 2017; 22, 136.
D Ramírez and J Caballero. Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules 2018; 23, 1038.
CA Lipinski, F Lombardo, BW Dominy and PJ Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001; 46, 3-26.
M Zhao, D Cascio, MR Sawaya and D Eisenberg. Structures of segments of α-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation. Protein Sci. 2011; 20, 996-1004.
JV Turner and S Agatonovic-Kustrin. In silico prediction of oral bioavailability. In: Comprehension medicinal chemistry II. Elsevier Science, Naterlands, 2007, p. 699-724.
H Pajouhesh and GR Lenz. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005; 2, 541-53.
E Leyden and P Tadi. Carbidopa. StatPearls, Florida, 2023.
MC Sorkun, A Khetan and S Er. AqSolDB, a curated reference set of aqueous solubility and 2D descriptors for a diverse set of compounds. Sci. Data 2019; 6, 143.
KT Savjani, AK Gajjar and JK Savjani. Drug solubility: Importance and enhancement techniques. ISRN Pharmacol. 2012; 2012, 195727.
A Daina, O Michielin and V Zoete. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017; 7, 42717.
LM Lagares, N Minovski and M Novič. Multiclass classifier for P-glycoprotein substrates, inhibitors, and non-active compounds. Molecules 2019; 24, 2006.
ML Amin. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013; 7, 27-34.
T Lynch and A Price. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 2007; 76, 391-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
